U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049185) titled 'QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma' on June 22.
Brief Summary: This is a single-arm, Simon's two-stage phase II clinical trial to evaluate the efficacy and safety of QL1706 (a dual PD-1 and CTLA-4 antibody) combined with celecoxib in patients with advanced esophageal squamous cell carcinoma (ESCC) who progressed after prior immune checkpoint inhibitor therapy.
Study Start Date: July 15
Study Type: INTERVENTIONAL
Condition:
Esophageal Squamous Cell Carcinoma
Intervention:
DRUG: QL1706 Plus Celecoxib Group
QL1706 (anti-PD-1/CTLA-4 bispecific antibody) will be administered at 5 mg/kg by intraveno...